New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2012
16:18 EDTWHR, DTSI, GS, AMTG, SRSL, KO, FSLR, JNJOn The Fly: Closing Wrap
Stocks on Wall Street were significantly higher, as a trio of earnings reports and a boost in the IMF's view of global growth prospects powered the market's rise. Stock futures were higher in pre-market trading on the strength of positive earnings reports from Coca-Cola (KO), Goldman Sachs (GS), and Johnson & Johnson (JNJ). The domestic economic data, which included fewer than expected housing starts and no increase in industrial production, was overshadowed by increased global and U.S. growth forecasts by the International Monetary Fund. With the earnings season beginning in earnest this week, investors appeared bullish about the prospects for solid numbers this quarter, if today's trading is taken as an indication... ECONOMIC EVENTS: In the U.S., housing starts for the month of March decreased 5.8%, versus expectations of an increase of 1%, but the number of building permits issued rose 4.5%, versus expectations of a decrease of 0.7%. Industrial production was reportedly flat in March, versus expectations for a 0.3% increase. Capacity utilization was in line with forecasts at 78.6%. In Europe, a German investor confidence survey was better than expected and Spanish benchmark yields eased back below 6%. Also, the International Monetary Fund said it sees world output growing 3.5% in 2012, raising its projection for United States growth to 2.1%. The IMF also said it sees growth in China slowing to 8.2% and real GDP in the euro area contracting in the first half of 2012 but then recovering... COMPANY NEWS: Coca Cola and Goldman Sachs both reported earnings and revenue that beat the Street's expectations, though Coke saw more of a favorable reaction from investors. Coca Cola shares rose 2.08% to $73.95 after its report, while Goldman fell 0.74% to $116.86. Johnson and Johnson also beat consensus for adjusted earnings, but its revenue came in below forecasts. Shares rose 0.38% to $64.22, making it one of the Dow's laggards during a session that saw all 30 stocks in the index post gains... MAJOR MOVERS: Among the notable gainers were SRS Labs (SRSL), up $2.53, or 36.88%, to $9.39, after agreeing to be acquired by DTS, Inc. (DTSI) in a cash-and-stock transaction valued at $9.50 per share, and First Solar (FSLR), up $2.14, or 10.28%, to $22.96, following its announcement of plans to cut its global workforce by approximately 2,000 positions, or about 30%, in response to conditions in Europe. Noteworthy losers included Apollo Residential Mortgage (AMTG), down $1.37, or 7.16%, to $17.76, after filing to sell 13.9M shares of its common stock, and Whirlpool (WHR), down $3.03, or 4.27%, to $68.00, after the International Trade Commission voted against imposing duties on refrigerators produced in South Korea and Mexico... INDICES: The Dow gained 194.13, or 1.50%, to 13,115.54; the Nasdaq rose 54.42, or 1.82%, to 3,042.82; and the S&P 500 added 21.21, or 1.55%, to 1,390.78.
News For KO;GS;JNJ;SRSL;DTSI;FSLR;AMTG;WHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
08:49 EDTJNJJohnson & Johnson: Priorities for free cash flow include dividends, repurchases
Subscribe for More Information
08:30 EDTJNJAchillion price target lowered to $16 from $25 at Leerink
Leerink says Achillion's deal with Johnson & Johnson (JNJ) increases the probability that it will be a competitive commercial-stage player in hepatitis C. The firm believes the collaboration limits share downside as well as upside by making the "home-run scenario of great combo data leading to an acquisition less likely." It lowered its price target for Achillion shares to $16 and keeps an Outperform rating on the name.
08:21 EDTGSATM data theft soars to highest rate in two decades, WSJ says
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson CEO Alex Gorsky says won't pursue pure-play strategy
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson to hold a meeting
Subscribe for More Information
07:51 EDTJNJAchillion shares remain undervalued after HCV pact with J&J, says Cowen
Subscribe for More Information
07:33 EDTJNJJ&J to file more than 10 new '$1B potenital' products by 2019
Subscribe for More Information
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
07:22 EDTKOCoca-Cola management to meet with SunTrust
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
13:11 EDTWHRWhirlpool strength attributed to favorable AHAM industry data
Subscribe for More Information
May 18, 2015
14:01 EDTWHRWhirlpool enters agreement to acquire American Dryer Corporation
Subscribe for More Information
07:40 EDTDTSIDTS, Inc. recent weakness a buying opportunity, says Cowen
Subscribe for More Information
May 15, 2015
16:28 EDTWHRAppaloosa Management gives quarterly update on stakes
Subscribe for More Information
11:47 EDTKOAnalysts mixed on Keurig after cold drink maker unveiling
Several research firms disagreed on the outlook for Keurig Green Mountain's (GMCR) upcoming at-home cold beverage maker, Keurig KOLD, after the company unveiled the product yesterday. SunTrust and Bernstein expressed major reservations about the product, while Susquehanna was more upbeat about the device and said the shares had reached a good entry point for investors. WHAT'S NEW: Keurig's management seemed to take a cautious view on the outlook for the device's sales, Bernstein analyst Ali Dibadj wrote. Additionally, the device and its pods "seemed a bit pricey" and large. However, the analyst, noting that the company hopes to eventually cut the price of the product to $200 from $300, called a potential $200 price point "more palatable for consumers." Furthermore, Dibadj says he has a hard time "fully understanding" the company's assertion that the device solves several problems. SunTrust analyst William Chappell, Jr. was impressed by the device's technology, but said he was concerned by the product's initial price and the investments that Keurig will have to make to launch the product. He kept a Neutral rating on the shares. BULLISH OUTLOOK:, Susquehanna analyst Pablo Zuanic said that most of the information on Kold was disappointing. The analyst said that he was disappointed by the device's high price and the fact that it will take a minute to make each drink. However, noting that SodaStream's (SODA) cold drink makers have penetrated 1.5% of U.S. households, the analyst says it is "not out of the question" that Kold can reach 3% household penetration in the U.S. by fiscal 2017-2018. If Kold does attain that milestone, Green Mountain's profits would double, the analyst stated. Zuanic remained upbeat on the company's long-term outlook and says that the stock is not currently reflecting any value for Kold. He believes that the stock has reached a good entry point, and kept a $140 price target and Positive rating on the shares. WHAT'S NOTABLE: Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. PRICE ACTION: In late morning trading, Keurig Green Mountain dropped 8.3% to $94.50, while SodaStream gained 2.5% to $22.25.
09:03 EDTWHRBofA/Merrill says to buy Home Depot, Lowe's and Whirlpool
Subscribe for More Information
08:48 EDTKOKeurig Green Mountain Keurig Cold price points worrisome, says SunTrust
After attending Keurig Green Mountain's (GMCR) Keurig Kold launch event, SunTrust says it was impressed by the device's technology but concerned about its initial price points and near-term investments needed to launch the product. The firm keeps a Neutral rating on the stock. Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. SodaStream (SODA) develops and markets at-home cold beverage makers. :
08:05 EDTKOBernstein has reservations about Keurig Green Mountain's Keurig Kold
After attending Keurig Green Mountain's (GMCR) Keurig Kold launch event, Bernstein says that it has a hard time understanding the device's value proposition and sensed some caution from the company about how quickly the device's penetration will rise and be accretive to earnings. The firm says the device and pods seem a bit expensive, while the brewer and pods are large. The firm believes that the taste of the product's Diet Coke drink was off, although regular Coke and others were good. Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. SodaStream (SODA) develops and markets at-home cold beverage makers.
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use